Revive Therapeutics Announces Proposed Shares for Debt Transaction
Revive Therapeutics (OTCQB: RVVTF) has announced a proposed shares for debt transaction to settle $150,000 in payables to arm's length parties through the issuance of 6,000,000 common shares at $0.025 per share. The issue price is calculated based on the 20-day VWAP of shares traded on the CSE.
The company aims to preserve cash for ongoing operations through this debt settlement. The transaction is subject to customary closing conditions, with shares to be issued having a four-month and one-day hold period from issuance date.
Revive Therapeutics (OTCQB: RVVTF) ha annunciato una proposta di operazione di conversione debito in azioni per saldare 150.000 dollari di debiti verso terzi indipendenti mediante l’emissione di 6.000.000 di azioni ordinarie al prezzo di 0,025 dollari per azione. Il prezzo di emissione è calcolato sulla base della media ponderata dei prezzi di chiusura (VWAP) delle azioni negoziate negli ultimi 20 giorni sulla CSE.
L’azienda intende preservare liquidità per le operazioni correnti tramite questa operazione di estinzione del debito. La transazione è soggetta alle consuete condizioni di chiusura, con le azioni emesse che saranno soggette a un periodo di blocco di quattro mesi e un giorno dalla data di emissione.
Revive Therapeutics (OTCQB: RVVTF) ha anunciado una propuesta de transacción de acciones por deuda para saldar $150,000 en cuentas por pagar a terceros independientes mediante la emisión de 6,000,000 acciones ordinarias a $0.025 por acción. El precio de emisión se calcula en base al VWAP de 20 días de las acciones negociadas en la CSE.
La compañía busca conservar efectivo para las operaciones en curso a través de esta liquidación de deuda. La transacción está sujeta a condiciones habituales de cierre, y las acciones emitidas tendrán un período de retención de cuatro meses y un día desde la fecha de emisión.
Revive Therapeutics (OTCQB: RVVTF)는 6,000,000주 일반주식을 주당 0.025달러에 발행하여 150,000달러의 채무를 독립된 제3자에게 상환하는 채무 대 주식 거래를 제안했다고 발표했습니다. 발행 가격은 CSE에서 거래된 최근 20일간의 거래량 가중 평균 가격(VWAP)을 기준으로 산정되었습니다.
회사는 이번 채무 상환을 통해 운영 자금을 보존하는 것을 목표로 하고 있습니다. 거래는 일반적인 종결 조건에 따르며, 발행된 주식은 발행일로부터 4개월 1일간의 보호예수 기간이 적용됩니다.
Revive Therapeutics (OTCQB : RVVTF) a annoncé une proposition de transaction d’actions contre dette visant à régler 150 000 $ de dettes envers des parties indépendantes par l’émission de 6 000 000 d’actions ordinaires au prix de 0,025 $ par action. Le prix d’émission est calculé sur la base du VWAP sur 20 jours des actions négociées à la CSE.
La société souhaite préserver sa trésorerie pour ses opérations courantes grâce à ce règlement de dette. La transaction est soumise aux conditions habituelles de clôture, les actions émises étant assorties d’une période de blocage de quatre mois et un jour à compter de la date d’émission.
Revive Therapeutics (OTCQB: RVVTF) hat eine vorgeschlagene Aktien-für-Schulden-Transaktion angekündigt, um Verbindlichkeiten in Höhe von 150.000 USD gegenüber unabhängigen Dritten durch die Ausgabe von 6.000.000 Stammaktien zu je 0,025 USD zu begleichen. Der Ausgabepreis basiert auf dem 20-Tage VWAP der an der CSE gehandelten Aktien.
Das Unternehmen beabsichtigt, durch diese Schuldenbegleichung liquide Mittel für den laufenden Betrieb zu erhalten. Die Transaktion unterliegt den üblichen Abschlussbedingungen, und die ausgegebenen Aktien unterliegen einer Haltefrist von vier Monaten und einem Tag ab Ausgabedatum.
- Preserves $150,000 in cash for ongoing operations
- Debt settlement with shares indicates financial management strategy
- 6,000,000 new shares issuance leads to dilution of existing shareholders
- Low share price of $0.025 indicates challenging market conditions
TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announces that it is proposing to settle an aggregate of
The Company believes that it is desirable to settle these outstanding payables by the issuance of the common shares in order to preserve the Company’s cash for ongoing operations.
Closing of the Shares for Debt Transaction is subject to customary closing conditions and the Company intends to close as soon as practicable. The common shares to be issued pursuant to the Shares for Debt Transaction will be subject to a hold period of four months and one day from the date of issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and six months ended December 31, 2024 ("MD&A"), dated February 24, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What is the value of Revive Therapeutics' (RVVTF) shares for debt transaction announced in April 2025?
What is the hold period for RVVTF shares issued in the debt settlement?
How was the share price determined for RVVTF's debt settlement?
Why is Revive Therapeutics (RVVTF) conducting a shares for debt transaction?
